Literature DB >> 7516012

Molecular mechanism of cibenzoline-induced anticholinergic action in single atrial myocytes: comparison with effect of disopyramide.

S N Wu1, T Nakajima, T Yamashita, E Hamada, H Hazama, K Iwasawa, M Omata, Y Kurachi.   

Abstract

The anticholinergic effects of cibenzoline were examined and compared with those of disopyramide in atrial myocytes isolated from guinea pig heart. The tight-seal whole-cell voltage clamp technique was performed with a patch pipette filled with guanosine-5'-triphosphate (GTP) or guanosine-5'-O-(3-thiotriphosphate) (GTP gamma S). In GTP-loaded cells, both acetylcholine (ACh) and adenosine (Ado) induced a specific K channel current through GTP-binding proteins by binding to the muscarinic and Ado receptors, respectively. Both cibenzoline and disopyramide suppressed the ACh-induced K current effectively in a concentration-dependent manner. The concentrations for half-maximal inhibition of the current (EC50) caused by cibenzoline and disopyramide were 8 and 3 microM, respectively. In GTP gamma S-loaded cells, the K current was irreversibly activated because GTP binding proteins were directly elicited by GTP gamma S. Cibenzoline effectively caused a decrease in the GTP gamma S-induced K current, whereas the extent of disopyramide action on the GTP gamma S-induced K current was much less. Cibenzoline also caused significant inhibition of Ado-induced K current in GTP-loaded cells. However, the action of disopyramide was less effective in inhibiting Ado-induced K current. These results indicate that cibenzoline has less potent anticholinergic effects than disopyramide in atrial myocytes. In addition, cibenzoline effectively inhibits the muscarinic K channel itself and/or GTP-binding proteins coupled to the channel, whereas the effect of disopyramide is attributed mainly to blockade of muscarinic receptors. These findings provide novel understanding of the molecular mechanism of anticholinergic action of cibenzoline.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516012     DOI: 10.1097/00005344-199404000-00014

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts.

Authors:  H Nakaya; Y Furusawa; T Ogura; M Tamagawa; H Uemura
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Inhibitory effects of aprindine on the delayed rectifier K+ current and the muscarinic acetylcholine receptor-operated K+ current in guinea-pig atrial cells.

Authors:  Y Ohmoto-Sekine; H Uemura; M Tamagawa; H Nakaya
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

3.  Interaction of class III antiarrhythmic drugs with muscarinic M2 and M3 receptors: radioligand binding and functional studies.

Authors:  H Uemura; Y Hara; M Endou; K Mori; H Nakaya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

4.  The bee venom peptide tertiapin underlines the role of I(KACh) in acetylcholine-induced atrioventricular blocks.

Authors:  M D Drici; S Diochot; C Terrenoire; G Romey; M Lazdunski
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

5.  Drug Therapy for Vagally-Mediated Atrial Fibrillation and Sympatho-Vagal Balance in the Genesis of Atrial Fibrillation: A Review of the Current Literature.

Authors:  Pattara Rattanawong; Jakrin Kewcharoen; Komandoor S Srivathsan; Win-Kuang Shen
Journal:  J Atr Fibrillation       Date:  2020-06-30

6.  SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells.

Authors:  Y Hara; H Nakaya
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.